279 related articles for article (PubMed ID: 20854202)
1. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
De Beaudrap P; Diallo MB; Landman R; Guèye NF; Ndiaye I; Diouf A; Kane CT; Etard JF; Girard PM; Sow PS; Delaporte E;
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1221-7. PubMed ID: 20854202
[TBL] [Abstract][Full Text] [Related]
2. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
[TBL] [Abstract][Full Text] [Related]
3. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
[TBL] [Abstract][Full Text] [Related]
4. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
[TBL] [Abstract][Full Text] [Related]
5. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
[TBL] [Abstract][Full Text] [Related]
6. The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.
Young J; Wang Q; Fux CA; Bernasconi E; Furrer H; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
HIV Med; 2014 Sep; 15(8):505-10. PubMed ID: 24641488
[TBL] [Abstract][Full Text] [Related]
7. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.
Bonjoch A; Echeverría P; Perez-Alvarez N; Puig J; Estany C; Clotet B; Negredo E
Antiviral Res; 2012 Oct; 96(1):65-9. PubMed ID: 22892171
[TBL] [Abstract][Full Text] [Related]
8. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
Kinai E; Hanabusa H
AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
[TBL] [Abstract][Full Text] [Related]
9. The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.
Wikman P; Safont P; Del Palacio M; Moreno A; Moreno S; Casado JL
Nephrol Dial Transplant; 2013 Aug; 28(8):2073-81. PubMed ID: 23739150
[TBL] [Abstract][Full Text] [Related]
10. Renal function with use of a tenofovir-containing initial antiretroviral regimen.
Gallant JE; Moore RD
AIDS; 2009 Sep; 23(15):1971-5. PubMed ID: 19696652
[TBL] [Abstract][Full Text] [Related]
11. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
[TBL] [Abstract][Full Text] [Related]
12. Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
Andrade-Fuentes K; Mata-Marín JA; López-De León JI; Manjarrez-Téllez B; Ramírez JL; Gaytan-Martínez J
AIDS Patient Care STDS; 2015 Apr; 29(4):181-5. PubMed ID: 25101526
[TBL] [Abstract][Full Text] [Related]
13. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Pontrelli G; Cotugno N; Amodio D; Zangari P; Tchidjou HK; Baldassari S; Palma P; Bernardi S
BMC Infect Dis; 2012 Jan; 12():18. PubMed ID: 22269183
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
15. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
16. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
17. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2.
Fafin C; Pugliese P; Durant J; Mondain V; Rahelinirina V; De Salvador F; Ceppi C; Perbost I; Rosenthal E; Roger PM; Cua E; Dellamonica P; Esnault V; Pradier C; Moranne O
Nephron Clin Pract; 2012; 120(4):c205-14. PubMed ID: 23037894
[TBL] [Abstract][Full Text] [Related]
18. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
Rasch MG; Engsig FN; Feldt-Rasmussen B; Kirk O; Kronborg G; Pedersen C; Gerstoft J; Obel N
Scand J Infect Dis; 2012 Sep; 44(9):689-96. PubMed ID: 22680981
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.
Woratanarat K; Kanjanabuch T; Suankratay C
J Med Assoc Thai; 2013 Apr; 96(4):432-9. PubMed ID: 23691697
[TBL] [Abstract][Full Text] [Related]
20. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Pradat P; Le Pogam MA; Okon JB; Trolliet P; Miailhes P; Brochier C; Maynard M; Bailly F; Zoulim F; Cotte L
J Viral Hepat; 2013 Sep; 20(9):650-7. PubMed ID: 23910650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
